drugset / Trial / NCT06942377

Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy

NCT06942377

Phase 2 Not yet recruiting 140 enrolled Peking University People's Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

To explore the treatment efficacy of Progesterone Therapeutic Regimen Plus Amlodipine in patients with early endometrial carcinoma (EEC) for conservative treatment.

Timeline

Start
2025-07-15
Primary completion
2027-01-01
Completion
2027-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg Oral
Subject Amlodipine Other / unclassified 10 mg Oral

Indications